PD-L1 expression and prognostic impact in glioblastoma

BACKGROUND: Therapeutic targeting of the immune checkpoints cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4) and PD-1/PD-L1 has demonstrated tumor regression in clinical trials, and phase 2 trials are ongoing in glioblastoma (GBM). Previous reports have suggested that responses are more frequen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Nduom, Edjah K., Wei, Jun, Yaghi, Nasser K., Huang, Neal, Kong, Ling-Yuan, Gabrusiewicz, Konrad, Ling, Xiaoyang, Zhou, Shouhao, Ivan, Cristina, Chen, Jie Qing, Burks, Jared K., Fuller, Greg N., Calin, George A., Conrad, Charles A., Creasy, Caitlin, Ritthipichai, Krit, Radvanyi, Laszlo, Heimberger, Amy B.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2016
Assuntos:
Basic and Translational Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4724183/
https://ncbi.nlm.nih.gov/pubmed/26323609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nov172
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados